韩国慢性阻塞性肺病患者的血中乙氨基酸细胞计数和治疗模式,使用真实世界的数据
Chin Kook Rhee1, Yu-Fan Ho2, Sumitra Shantakumar2
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
The Korean journal of internal medicine
|January 8, 2025
概括
在韩国慢性阻塞性肺病 (COPD) 患者中,血中乙氨基酸细胞数量 (BEC) 稳定,支持其作为吸入性皮质类固醇 (ICS) 反应和恶化风险的生物标志物的使用.
科学领域:
- 肺部医学 肺部医学
- 生物标志物研究 生物标志物研究
- 临床流行病学 临床流行病学
背景情况:
- 慢性阻塞性肺病 (COPD) 管理指南强调预防恶化.
- 血中乙氨基酸细胞计数 (BEC) 被认为是吸入性皮质类固醇 (ICS) 反应的生物标志物.
研究的目的:
- 描述韩国COPD患者中BEC的分布和稳定性.
- 了解与BEC相关的现实世界治疗模式.
主要方法:
- 对KOrea COPD亚组研究 (KOCOSS) 注册表 (2012-2018) 的回顾性分析.
- 使用类内相关系数 (ICC) 评估BEC稳定性.
- 恶化症被定义为在过去12个月内出现≥1次恶化症的患者.
主要成果:
- 包括2661名COPD患者 (平均年龄68.6岁,男性92.0%).
- 平均BEC在恶化剂与非恶化剂中较高.
- 随着时间的推移,BEC在患有≥2次恶化症 (ICC=0.44) 和非恶化症 (ICC=0.57) 的患者中不太稳定.
- 在BEC≥300细胞/μL的患者中,三重治疗是常见的 (43.8%).
结论:
- 在韩国COPD患者中,BEC测量稳定且可重现.
- 支持BEC作为COPD管理的潜在生物标志物的实用性.
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
COPD: Management Using Bronchodilators and Corticosteroids
177
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
177
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K


